Key COVID-19 Studies Influencing My Practice Following IDWeek 2022*

Join expert faculty in a live, interactive, CME/CE/CPE-certified webinar providing rapid updates and answers to your questions on key COVID-19 prevention and treatment strategies from the IDWeek 2022 scientific meeting.


Program Overview (5 mins)

Key COVID-19 Studies Influencing My Practice Following IDWeek 2022 (30 mins)

  • Vaccines and monoclonal antibodies for COVID-19 prevention
  • COVID-19 screening and diagnostics
  • Safety and efficacy of COVID-19 therapeutics

Question and Answer Session (10 mins)


Date / Time
Event Details


Gregory Huhn, MD, MPHTM

Professor of Medicine
Department of Infectious Diseases
Rush University Medical Center
Interim Chief
Division of Infectious Diseases
Cook County Health
Chicago, Illinois

Princy N. Kumar, MD, FIDSA, MACP

Professor of Medicine and Microbiology
Division of Infectious Diseases and Travel Medicine
Senior Associate Dean of Students
Georgetown University School of Medicine
Washington, DC

Cristina Mussini, MD

Head of Department of Infectious Diseases and Tropical Medicine
Full Professor of Infectious Diseases

Infectious Diseases Clinics, University Hospital
University of Modena and Reggio Emilia
Modena, Italy

Paul E. Sax, MD

Clinical Director
HIV Program and Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Goal Statement
The goal of this activity is to improve learners’ competence in translating the most clinically significant data from IDWeek 2022 into practical management strategies for individuals at risk of or diagnosed with COVID-19.

Target Audience
This program is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for patients at risk of or diagnosed with COVID-19.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply safety and efficacy data from recent clinical studies of evolving therapeutics for SARS-CoV-2 in ongoing treatment of patients with COVID-19
  • Integrate new data from studies of vaccines and monoclonal antibodies into prevention strategies for SARS-CoV-2 infection
  • Interpret findings of studies on screening and diagnostics for SARS-CoV-2 and SARS-CoV-2 antibodies
  • Interpret findings of studies on COVID-19 prevention and treatment strategies in vulnerable populations including immunocompromised cohorts


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-255-L01-P

Type of Activity: Knowledge

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.